(3.238.184.78)
Users online: 2238    [ij] [ij] [ij] 
Email id
 

Asian Journal of Research in Pharmaceutical Science
Year : 2018, Volume : 8, Issue : 1
First page : ( 45) Last page : ( 47)
Print ISSN : 2231-5640. Online ISSN : 2231-5659.
Article DOI : 10.5958/2231-5659.2018.00010.3

Probenecid Act as an Uricosuric agent: A Review

Mr. Jain Mayur S.*, Dr. Barhate Shashikant D., Mr. Gayakwad Bhushan P.

Shree Sureshadada Jain Institutes of Pharmaceutical Education and Research, Jammer, Maharashtra (India)

*Corresponding Author E-mail: mayurjain176@gmail.com

Online published on 2 June, 2018.

Abstract

Probenecid is s prototypical uricosuric agent which is predominantly used to inhibit the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. Probenecid, also sold under the brand name Probalan, is a medication that increases uric acid excretion in the urine. It is primarily used in treatment of gout and hyperuricemia. Probenecid was developed as an alternative to caronamide to competitively inhibit renal excretion of some drugs, thereby increasing their plasma concentration and prolonging their effects.

Top

Keywords

Probenecid, Uricosuric agent, Gout.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
458,458,031 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.